HAEM5:Acute undifferentiated leukaemia - Revision history

Bailey.Glen at 17:08, 3 July 2025

2025-07-03T17:08:17Z

← Older revision		Revision as of 12:08, 3 July 2025
Line 34:		Line 34:
	\|}		\|}

	~~==WHO Essential and Desirable Genetic Diagnostic Criteria==~~
	<span style="color:#0070C0">(''Instructions: The table will have the diagnostic criteria from the WHO book <u>autocompleted</u>; remove any <u>non</u>-genetics related criteria. If applicable, add text about other classification'' ''systems that define this entity and specify how the genetics-related criteria differ.'')</span>
	~~{\| class="wikitable"~~
	\|+
	\|WHO Essential Criteria (Genetics)*
	\|
	\|-
	\|WHO Desirable Criteria (Genetics)*
	\|
	\|-
	~~\|Other Classification~~
	\|
	\|}
	<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].
	==Related Terminology==		==Related Terminology==

Bailey.Glen at 21:27, 25 May 2025

2025-05-25T21:27:42Z

← Older revision		Revision as of 16:27, 25 May 2025
Line 149:		Line 149:
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Chr #!!~~'''~~Gain, Loss, Amp, LOH~~'''~~!!~~'''~~Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]~~'''~~!!~~'''~~Relevant Gene(s)~~'''~~		!Chr #!!Gain, Loss, Amp, LOH!!Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]!!Relevant Gene(s)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>		\|<span class="blue-text">EXAMPLE:</span>
Line 214:		Line 214:
	!Chromosomal Pattern		!Chromosomal Pattern
	!Molecular Pathogenesis		!Molecular Pathogenesis
	!~~'''~~Prevalence -~~'''~~		!Prevalence -
	~~'''~~Common >20%, Recurrent 5-20% or Rare <5% (Disease)~~'''~~		Common >20%, Recurrent 5-20% or Rare <5% (Disease)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>		\|<span class="blue-text">EXAMPLE:</span>
Line 258:		Line 258:
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Gene!!~~'''~~Genetic Alteration~~'''~~!!~~'''~~Tumor Suppressor Gene, Oncogene, Other~~'''~~!!~~'''~~Prevalence -~~'''~~		!Gene!!Genetic Alteration!!Tumor Suppressor Gene, Oncogene, Other!!Prevalence -
	~~'''~~Common >20%, Recurrent 5-20% or Rare <5% (Disease)~~'''~~		Common >20%, Recurrent 5-20% or Rare <5% (Disease)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T ~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>''EGFR''		\|<span class="blue-text">EXAMPLE:</span>''EGFR''

Bailey.Glen at 20:04, 25 May 2025

2025-05-25T20:04:05Z

← Older revision		Revision as of 15:04, 25 May 2025
Line 49:		Line 49:
	<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].		<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].
	==Related Terminology==		==Related Terminology==
	~~<span style="color:#0070C0">(''Instructions: The table will have the related terminology from the WHO <u>autocompleted</u>.)''</span>~~
	{\| class="wikitable"		{\| class="wikitable"
	\|+		\|+
	\|Acceptable		\|Acceptable
	\|		\|N/A
	\|-		\|-
	\|Not Recommended		\|Not Recommended
	\|		\|Stem cell acute leukaemia
	\|}		\|}

Bailey.Glen at 17:31, 24 March 2025

2025-03-24T17:31:39Z

← Older revision		Revision as of 12:31, 24 March 2025
Line 1:		Line 1:
	{{DISPLAYTITLE:Acute undifferentiated leukaemia}}		{{DISPLAYTITLE:Acute undifferentiated leukaemia}}

	[[HAEM5:Table_of_Contents\|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]		[[HAEM5:Table_of_Contents\|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]

Line 13:		Line 12:

	Amelia Nakanishi, MD and Shashi Shetty, PhD		Amelia Nakanishi, MD and Shashi Shetty, PhD

	~~__TOC__~~

	==WHO Classification of Disease==		==WHO Classification of Disease==

Bailey.Glen: Removed old template contents

2025-02-11T14:40:40Z

Removed old template contents

Show changes

Bailey.Glen at 18:39, 10 February 2025

2025-02-10T18:39:14Z

Show changes

Bailey.Glen at 18:11, 10 February 2025

2025-02-10T18:11:09Z

← Older revision		Revision as of 13:11, 10 February 2025
Line 71:		Line 71:


	<blockquote class='blockedit'>{{Box-round\|title=v4:Clinical Features\|The content below was from the old template. Please incorporate above.}}		<blockquote class='blockedit'>{{Box-round\|title=v4:Clinical Features\|The content below was from the old template. Please incorporate above.}}</blockquote>

	In one study of 16 cases of adults with AUL, the median age was 63 years (range: 24-84 years) and patients could achieve clinical remission after allogeneic stem cell transplantation<ref name=":2">{{Cite journal\|displayauthors=1\|last=Heesch\|first=Sandra\|last2=Neumann\|first2=Martin\|last3=Schwartz\|first3=Stefan\|last4=Bartram\|first4=Isabelle\|last5=Schlee\|first5=Cornelia\|last6=Burmeister\|first6=Thomas\|last7=Hänel\|first7=Matthias\|last8=Ganser\|first8=Arnold\|last9=Heuser\|first9=Michael\|date=2013\|title=Acute leukemias of ambiguous lineage in adults: molecular and clinical characterization\|url=https://pubmed.ncbi.nlm.nih.gov/23412561\|journal=Annals of Hematology\|volume=92\|issue=6\|pages=747–758\|doi=10.1007/s00277-013-1694-4\|issn=1432-0584\|pmid=23412561\|via=}}</ref>. In previous studies that weakly suggest ALL induction regimens over AML induction regimens, there may be selection bias in the patients who were well enough to be transplant candidates<ref>{{Cite journal\|displayauthors=1\|last=Weinberg\|first=Olga K.\|last2=Hasserjian\|first2=Robert P.\|last3=Baraban\|first3=Ezra\|last4=Ok\|first4=Chi Young\|last5=Geyer\|first5=Julia T.\|last6=Philip\|first6=John K. S. S.\|last7=Kurzer\|first7=Jason H.\|last8=Rogers\|first8=Heesun J.\|last9=Nardi\|first9=Valentina\|date=2019\|title=Clinical, immunophenotypic, and genomic findings of acute undifferentiated leukemia and comparison to acute myeloid leukemia with minimal differentiation: a study from the bone marrow pathology group\|url=https://pubmed.ncbi.nlm.nih.gov/31000771\|journal=Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc\|volume=32\|issue=9\|pages=1373–1385\|doi=10.1038/s41379-019-0263-3\|issn=1530-0285\|pmid=31000771\|via=}}</ref>.		In one study of 16 cases of adults with AUL, the median age was 63 years (range: 24-84 years) and patients could achieve clinical remission after allogeneic stem cell transplantation<ref name=":2">{{Cite journal\|displayauthors=1\|last=Heesch\|first=Sandra\|last2=Neumann\|first2=Martin\|last3=Schwartz\|first3=Stefan\|last4=Bartram\|first4=Isabelle\|last5=Schlee\|first5=Cornelia\|last6=Burmeister\|first6=Thomas\|last7=Hänel\|first7=Matthias\|last8=Ganser\|first8=Arnold\|last9=Heuser\|first9=Michael\|date=2013\|title=Acute leukemias of ambiguous lineage in adults: molecular and clinical characterization\|url=https://pubmed.ncbi.nlm.nih.gov/23412561\|journal=Annals of Hematology\|volume=92\|issue=6\|pages=747–758\|doi=10.1007/s00277-013-1694-4\|issn=1432-0584\|pmid=23412561\|via=}}</ref>. In previous studies that weakly suggest ALL induction regimens over AML induction regimens, there may be selection bias in the patients who were well enough to be transplant candidates<ref>{{Cite journal\|displayauthors=1\|last=Weinberg\|first=Olga K.\|last2=Hasserjian\|first2=Robert P.\|last3=Baraban\|first3=Ezra\|last4=Ok\|first4=Chi Young\|last5=Geyer\|first5=Julia T.\|last6=Philip\|first6=John K. S. S.\|last7=Kurzer\|first7=Jason H.\|last8=Rogers\|first8=Heesun J.\|last9=Nardi\|first9=Valentina\|date=2019\|title=Clinical, immunophenotypic, and genomic findings of acute undifferentiated leukemia and comparison to acute myeloid leukemia with minimal differentiation: a study from the bone marrow pathology group\|url=https://pubmed.ncbi.nlm.nih.gov/31000771\|journal=Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc\|volume=32\|issue=9\|pages=1373–1385\|doi=10.1038/s41379-019-0263-3\|issn=1530-0285\|pmid=31000771\|via=}}</ref>.
Line 77:		Line 77:
	In children, based on limited clinical information in the literature, AUL has been associated with a poor prognosis<ref>{{Cite journal\|displayauthors=1\|last=Lee\|first=Hyun Gyung\|last2=Baek\|first2=Hee Jo\|last3=Kim\|first3=Ho Sung\|last4=Park\|first4=Soo Min\|last5=Hwang\|first5=Tai Ju\|last6=Kook\|first6=Hoon\|date=2019\|title=Biphenotypic acute leukemia or acute leukemia of ambiguous lineage in childhood: clinical characteristics and outcome\|url=https://pubmed.ncbi.nlm.nih.gov/30956966\|journal=Blood Research\|volume=54\|issue=1\|pages=63–73\|doi=10.5045/br.2019.54.1.63\|issn=2287-979X\|pmc=6439300\|pmid=30956966\|via=}}</ref>.		In children, based on limited clinical information in the literature, AUL has been associated with a poor prognosis<ref>{{Cite journal\|displayauthors=1\|last=Lee\|first=Hyun Gyung\|last2=Baek\|first2=Hee Jo\|last3=Kim\|first3=Ho Sung\|last4=Park\|first4=Soo Min\|last5=Hwang\|first5=Tai Ju\|last6=Kook\|first6=Hoon\|date=2019\|title=Biphenotypic acute leukemia or acute leukemia of ambiguous lineage in childhood: clinical characteristics and outcome\|url=https://pubmed.ncbi.nlm.nih.gov/30956966\|journal=Blood Research\|volume=54\|issue=1\|pages=63–73\|doi=10.5045/br.2019.54.1.63\|issn=2287-979X\|pmc=6439300\|pmid=30956966\|via=}}</ref>.

			<blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
	</blockquote>		</blockquote>
	==Sites of Involvement==		==Sites of Involvement==
Line 104:		Line 107:


	<blockquote class='blockedit'>{{Box-round\|title=v4:Immunophenotype\|The content below was from the old template. Please incorporate above.}}		<blockquote class='blockedit'>{{Box-round\|title=v4:Immunophenotype\|The content below was from the old template. Please incorporate above.}}</blockquote>

	Per WHO 2017, AUL blasts should express no more than one membrane marker for any lineage.		Per WHO 2017, AUL blasts should express no more than one membrane marker for any lineage.
Line 132:		Line 135:
	-See [[HAEM4:Acute Leukemias of Ambiguous Lineage]] for assigning lineage assignment.		-See [[HAEM4:Acute Leukemias of Ambiguous Lineage]] for assigning lineage assignment.

			<blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
	</blockquote>		</blockquote>
	==Chromosomal Rearrangements (Gene Fusions)==		==Chromosomal Rearrangements (Gene Fusions)==
Line 156:		Line 162:


	<blockquote class='blockedit'>{{Box-round\|title=v4:Chromosomal Rearrangements (Gene Fusions)\|The content below was from the old template. Please incorporate above.}}		<blockquote class='blockedit'>{{Box-round\|title=v4:Chromosomal Rearrangements (Gene Fusions)\|The content below was from the old template. Please incorporate above.}}</blockquote>

	NA		NA
			<blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
	</blockquote>		</blockquote>

Line 166:		Line 175:
	* Individual Region Genomic Gain/Loss/LOH		* Individual Region Genomic Gain/Loss/LOH
	* Characteristic Chromosomal Patterns		* Characteristic Chromosomal Patterns
	* Gene Mutations (SNV/INDEL)}}		* Gene Mutations (SNV/INDEL)}}</blockquote>

	There is evidence that the genes associated with poor prognosis in acute leukemias, BAALC, ERG, and MN1, are also overexpressed in AUL<ref name=":0" />.		There is evidence that the genes associated with poor prognosis in acute leukemias, BAALC, ERG, and MN1, are also overexpressed in AUL<ref name=":0" />.

			<blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
	</blockquote>		</blockquote>
	==Individual Region Genomic Gain / Loss / LOH==		==Individual Region Genomic Gain / Loss / LOH==
Line 218:		Line 230:
	\|}		\|}

	<blockquote class='blockedit'>{{Box-round\|title=v4:Genomic Gain/Loss/LOH\|The content below was from the old template. Please incorporate above.}}		<blockquote class='blockedit'>{{Box-round\|title=v4:Genomic Gain/Loss/LOH\|The content below was from the old template. Please incorporate above.}}</blockquote>

	NA		NA
			<blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
	</blockquote>		</blockquote>
	==Characteristic Chromosomal Patterns==		==Characteristic Chromosomal Patterns==
Line 245:		Line 260:
	\|}		\|}

	<blockquote class='blockedit'>{{Box-round\|title=v4:Characteristic Chromosomal Aberrations / Patterns\|The content below was from the old template. Please incorporate above.}}		<blockquote class='blockedit'>{{Box-round\|title=v4:Characteristic Chromosomal Aberrations / Patterns\|The content below was from the old template. Please incorporate above.}}</blockquote>

	AUL is associated with a high rate of chromosomal abnormalities, but have no characteristic abnormalities<ref name=":2" />.		AUL is associated with a high rate of chromosomal abnormalities, but have no characteristic abnormalities<ref name=":2" />.

			<blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
	</blockquote>		</blockquote>
	==Gene Mutations (SNV / INDEL)==		==Gene Mutations (SNV / INDEL)==
Line 284:		Line 302:


	<blockquote class='blockedit'>{{Box-round\|title=v4:Gene Mutations (SNV/INDEL)\|The content below was from the old template. Please incorporate above.}}		<blockquote class='blockedit'>{{Box-round\|title=v4:Gene Mutations (SNV/INDEL)\|The content below was from the old template. Please incorporate above.}}</blockquote>

	PHF6 a tumor suppressor gene may have implications in AUL though the evidence is limited.		PHF6 a tumor suppressor gene may have implications in AUL though the evidence is limited.
Line 290:		Line 308:
	NA		NA

			<blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
	</blockquote>		</blockquote>
	==Epigenomic Alterations==		==Epigenomic Alterations==
Line 315:		Line 336:
	\|}		\|}

	<blockquote class='blockedit'>{{Box-round\|title=v4:Genes and Main Pathways Involved\|The content below was from the old template. Please incorporate above.}}		<blockquote class='blockedit'>{{Box-round\|title=v4:Genes and Main Pathways Involved\|The content below was from the old template. Please incorporate above.}}</blockquote>

	Overexpression of BAALC, ERG, and MN1<ref name=":0" />.		Overexpression of BAALC, ERG, and MN1<ref name=":0" />.

			<blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
	</blockquote>		</blockquote>
	==Genetic Diagnostic Testing Methods==		==Genetic Diagnostic Testing Methods==

Bailey.Glen at 22:23, 6 September 2024

2024-09-06T22:23:24Z

← Older revision		Revision as of 17:23, 6 September 2024
Line 15:		Line 15:
	__TOC__		__TOC__

	==~~Cancer Category / Type~~==		==WHO Classification of Disease==

	~~Hematologic malignancy/~~ Acute ~~leukemia~~		{\| class="wikitable"
			!Structure
	~~==Cancer Sub~~-~~Classification / Subtype==~~		!Disease
			\|-
	Acute ~~Leukemias~~ of ~~Ambiguous Lineage~~ (~~WHO 2017~~)/ Acute ~~Undifferentiated Leukemia (AUL)~~		\|Book
			\|Haematolymphoid Tumours (5th ed.)
			\|-
			\|Category
			\|Myeloid proliferations and neoplasms
			\|-
			\|Family
			\|Acute leukaemias of mixed or ambiguous lineage
			\|-
			\|Type
			\|Acute leukaemia of ambiguous lineage, immunophenotypically defined
			\|-
			\|Subtype(s)
			\|Acute undifferentiated leukaemia
			\|}

	==Definition / Description of Disease==		==Definition / Description of Disease==

Bailey.Glen at 21:49, 6 September 2024

2024-09-06T21:49:48Z

Show changes

Bailey.Glen: Undo revision 14811 by Bailey.Glen (talk)

2024-09-06T19:53:15Z

Undo revision 14811 by Bailey.Glen (talk)

Show changes